ATEA PHARMACEUTICALS INC (AVIR) Stock News

NASDAQ:AVIR - Nasdaq - US04683R1068 - Common Stock - Currency: USD

3.43 0 (0%)

After market: 3.43 0 (0%)

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

AVIR Latest News, Press Relases and Analysis

All

Press Releases

a month ago - By: Atea Pharmaceuticals, Inc.

Atea Pharmaceuticals Announces Continued Advancement of Global Phase 3 HCV Program with Dosing of First Patient in C-FORWARD Outside North America

a month ago - By: Atea Pharmaceuticals, Inc.

Atea Pharmaceuticals Announces Continued Advancement of Global Phase 3 HCV Program with Dosing of First Patient in C-FORWARD Outside North America

2 months ago - By: Atea Pharmaceuticals, Inc.

Atea Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

2 months ago - By: Atea Pharmaceuticals, Inc.

Atea Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

4 months ago - By: Atea Pharmaceuticals, Inc.

Atea Pharmaceuticals Issues Statement Regarding Director Nominations

3 months ago - By: Atea Pharmaceuticals, Inc.

Atea Pharmaceuticals Announces Full Results from Phase 2 Study of Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus (HCV) Presented at EASL Congress 2025

3 months ago - By: Atea Pharmaceuticals, Inc.

Atea Pharmaceuticals to Host Virtual HCV KOL Panel on May 14, 2025

3 months ago - By: Atea Pharmaceuticals, Inc.

Atea Pharmaceuticals to Present New Data Showcasing Potential Best-in-Class Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus at EASL Congress 2025

3 months ago - By: Atea Pharmaceuticals, Inc.

Atea Pharmaceuticals to Present New Data Showcasing Potential Best-in-Class Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus at EASL Congress 2025

3 months ago - By: Atea Pharmaceuticals, Inc.

Atea Pharmaceuticals Appoints Howard H. Berman to Board of Directors and Announces Share Repurchase Program

3 months ago - By: Atea Pharmaceuticals, Inc. - Mentions: COYA

Atea Pharmaceuticals Appoints Howard H. Berman to Board of Directors and Announces Share Repurchase Program

3 months ago - By: Atea Pharmaceuticals, Inc.

Atea Pharmaceuticals Announces Dosing of First Patient in C-BEYOND, Phase 3 Study Evaluating Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus

3 months ago - By: Atea Pharmaceuticals, Inc.

Atea Pharmaceuticals Announces Dosing of First Patient in C-BEYOND, Phase 3 Study Evaluating Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus

4 months ago - By: Atea Pharmaceuticals, Inc.

Atea Pharmaceuticals Highlights Actions Underway to Enhance Shareholder Value

4 months ago - By: Atea Pharmaceuticals, Inc.

Atea Pharmaceuticals Highlights Actions Underway to Enhance Shareholder Value

4 months ago - By: On Behalf of The Radoff-JEC Group

The Radoff-JEC Group Nominates Three Highly Qualified Candidates for Election to the Atea Pharmaceuticals Board of Directors

4 months ago - By: Atea Pharmaceuticals, Inc.

Atea Pharmaceuticals Issues Statement Regarding Director Nominations

4 months ago - By: Atea Pharmaceuticals, Inc.

Atea Pharmaceuticals Announces Presentation of Bemnifosbuvir Preclinical Data at the 38th International Conference on Antiviral Research (ICAR) 2025

4 months ago - By: Atea Pharmaceuticals, Inc.

Atea Pharmaceuticals Announces Presentation of Bemnifosbuvir Preclinical Data at the 38th International Conference on Antiviral Research (ICAR) 2025

5 months ago - By: Benzinga

Atea Pharma Cuts Workforce By 25%, Expects $15 Million In Cost Savings, Plans Phase 3 Hepatitis C Trial

5 months ago - By: Atea Pharmaceuticals, Inc.

Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

5 months ago - By: Atea Pharmaceuticals, Inc.

Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

5 months ago - By: Atea Pharmaceuticals, Inc.

Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2024 Financial Results Conference Call on March 6, 2025

5 months ago - By: Atea Pharmaceuticals, Inc.

Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2024 Financial Results Conference Call on March 6, 2025

5 months ago - By: Benzinga - Mentions: KVHI VEL HCP MODV ...

Earnings Scheduled For March 6, 2025

5 months ago - By: Atea Pharmaceuticals, Inc.

Atea Pharmaceuticals Appoints Arthur S. Kirsch to Board of Directors

5 months ago - By: Atea Pharmaceuticals, Inc. - Mentions: LQDA KDMN

Atea Pharmaceuticals Appoints Arthur S. Kirsch to Board of Directors

6 months ago - By: Atea Pharmaceuticals, Inc.

Atea Pharmaceuticals to Highlight 2025 Strategic Priorities at the 43rd Annual J.P. Morgan Healthcare Conference

7 months ago - By: Atea Pharmaceuticals, Inc.

Atea Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

7 months ago - By: Atea Pharmaceuticals, Inc.

Atea Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

7 months ago - By: Atea Pharmaceuticals, Inc.

Atea Pharmaceuticals Retains Financial Advisor to Explore Strategic Partnerships

7 months ago - By: Atea Pharmaceuticals, Inc.

Atea Pharmaceuticals Retains Financial Advisor to Explore Strategic Partnerships

8 months ago - By: Atea Pharmaceuticals, Inc.

Atea Pharmaceuticals Announces Positive Results from Phase 2 Study of Bemnifosbuvir and Ruzasvir Regimen for Treatment of Hepatitis C Virus (HCV)

8 months ago - By: Atea Pharmaceuticals, Inc.

Atea Pharmaceuticals Announces Positive Results from Phase 2 Study of Bemnifosbuvir and Ruzasvir Regimen for Treatment of Hepatitis C Virus (HCV)

8 months ago - By: Atea Pharmaceuticals, Inc.

Atea Pharmaceuticals to Present and Provide a Business Update at the 7th Annual Evercore HealthCONx Conference